EUREMAB is an Italian biotech company and a spinoff of the University of Torino. It fosters and supports the launching of biotech startups with disruptive innovation potential. Much more than a service provider, it gives life to game-changing ideas in the field of biotechnology, drug discovery and healthcare.
Did you know that EUREMAB originates from a collaboration between the University of Torino and the Belgian biotech argenx? Did you know that EUREMAB co-founded and launched another successful Belgian biotech, AgomAb Therapeutics? Did you know that EUREMAB has developed the first agonistic antibodies for the treatment of fibrosis? To find out what's cookin' at EUREMAB, follow this page and stay tuned!
Company Details
- Employees
- 4
- Founded
- -
- Address
- Via Nizza, 52, Molecular Biotechnology Center,italy
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- biotechnology, antibody engineering, animal models of human diseases, custom services, contract research organization, startup support.
- HQ
- Turin, Piedmont
Euremab Questions
Euremab's LinkedIn profile is https://it.linkedin.com/company/euremab
Euremab has
4 employees.
View email and phone details for 4
employees at Euremab.
Euremab's industry is
Biotechnology Research
Euremab's categories are Biotechnology Research
Euremab's founding year is 2016
